Sarepta Therapeutics (SRPT) shares plummeted 5.16% during intraday trading on Friday, reflecting significant negative sentiment toward the biopharmaceutical company.

The sharp decline followed news that Wells Fargo analyst Yanan Zhu lowered the firm's price target on Sarepta to $38 from $45, representing a substantial downward revision. While maintaining an Overweight rating on the shares, the reduced target price suggests concerns about the company's valuation or near-term prospects.